Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Fixer-Upper” Encysive’s Thelin Is Pfizer’s Problem Now

This article was originally published in The Pink Sheet Daily

Executive Summary

Pharma knight rescues Encysive, with its troubled Thelin for pulmonary hypertension, in a deal worth about $200 million.

You may also be interested in...



Another Disappointment For Pfizer; PAH Drug Withdrawn

Pfizer withdraws Thelin from the EU, Canada and Australia due to liver toxicity.

Another Disappointment For Pfizer; PAH Drug Withdrawn

Pfizer withdraws Thelin from the EU, Canada and Australia due to liver toxicity.

FDA Not More Conservative Than EU, Jenkins Says; Investors Not Convinced

Perceptions that FDA is more conservative in its approval standards than its European regulatory counterpart are misguided and largely overblown, Office of New Drugs Director John Jenkins said

Related Content

Topics

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel